title: What are our pharmacotherapeutic options for MERS-CoV?
abstract: Since the initial description of Middle East Respiratory Syndrome-coronavirus (MERS-CoV), the disease has been associated with a high case-fatality rate. There is a lack of proven effective medications for therapy of MERS-CoV. The current knowledge of therapeutic options for MERS-CoV is based on the experience from SARS-CoV and from in vitro studies. In this article we review the different therapeutics available for MERS-CoV from SARS experience, in vitro and animal studies of this emerging disease.
authors.affiliation: Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
authors.forename: Jaffar A
authors.initials: JA
authors.lastname: Al-Tawfiq
authors.forename: Ziad A
authors.initials: ZA
authors.lastname: Memish
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018352:Coronavirus Infections / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000821:virology; D004359:Drug Therapy, Combination; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D065207:Middle East Respiratory Syndrome Coronavirus / Q000187:drug effects*; D045473:Severe acute respiratory syndrome-related coronavirus / Q000187:drug effects; D045169:Severe Acute Respiratory Syndrome / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000821:virology
chemical_list: D000998:Antiviral Agents; D007155:Immunologic Factors